You are here: Industry Insights > Opdivo

News List

NICE says no for Opdivo in urothelial carcinoma pharmatimes
October 23, 2017
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).
FDA accepts Bristol-Myers Squibb's application for Opdivo (nivolumab) in patients with resected high worldpharmanews
October 18, 2017
FDA has accepted for priority review its supplemental Biologics License Application for Opdivo to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer pharmafile
October 16, 2017
On initial review of the drug, NICE found that evidence on Opdivo’s efficacy in head and neck cancer proved inconclusive and could not approve it for use on the NHS.
Japan approves Opdivo, the first-ever immuno-oncology agent for unresectable advanced/recurrent gast pharmaasia
September 27, 2017
Opdivo is the first and only immuno-oncology treatment to demonstrate survival benefit in patients who underwent two or more prior treatments.
NICE backs use of Opdivo for lung cancer pharmatimes
September 21, 2017
Bristol-Myers Squibb’s Opdivo is being recommended by the National Institute for Health and Care Excellence to treat a certain form of lung cancer on the NHS in England, via the Cancer Drugs Fund.
BMS’ Opdivo to finally be made available to lung cancer patients in the UK pharmafile
September 21, 2017
It is two and a half years since patients with lung cancer in the US were able to receive Bristol-Myers Squibb’s Opdivo for treatment, the UK has finally caught up after NICE's approval of the drug.
Mixed results for BMS’ Opdivo, Yervoy combo in kidney cancer pharmatimes
August 17, 2017
A combination of Bristol-Myers Squibb’s Opdivo and Yervoy has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients with renal cancer.
look back at 10 years of industry-watching fiercepharma
August 08, 2017
With 10 years in our rearview mirror, FiercePharma is looking back at the ways the industry has changed (and stayed the same).
Latest Progress of PD-1 Inhibitors: Keytruda and Opdivo are close en-cphi.cn
August 04, 2017
There is a subtle change in the competition situation of PD-1/PD-L1 market, the gap between Keytruda and Opdivo being significantly decreasing, becoming the main impetus to drive the rapid expansion of the entire PD-1/PD-L1 drug market.
Opdivo (Nivolumab) Receives 1st August PBS Listings For Advanced Lung Cancer And Advanced Kidney Can firstwordpharma
August 02, 2017
OPDIVO® becomes the first and only immuno-oncology therapy PBS listed for advanced lung and kidney cancer1,2

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page